Is the therapeutic effect of talquetamab-tgvs significant?

Talquetamab is a new type of immunotherapy drug mainly used to treat patients with relapsed or refractory multiple myeloma. Multiple myeloma is a stubborn and rapidly progressing blood cancer. Traditional treatments include chemotherapy, immunotherapy and stem cell transplantation, but many patients experience recurrence or drug resistance of the disease after treatment. Therefore, it is particularly important to develop new treatments for this condition.

In a pivotal clinical study titled"TG-1701," researchers evaluated the efficacy of taquinutumab in patients with relapsed or refractory multiple myeloma. The study enrolled a total of 288 patients who had received three or more previous treatments and whose disease still recurred or was difficult to control. Patients were randomly divided into two groups, one receiving 0.4 mg/kg body weight of taquitumab every week, and the other group receiving 0.8 mg/kg of body weight every 2 weeks. The study did not directly compare taquitumab to other treatments, but instead evaluated the drug's efficacy alone.

Results of the study show that Taquitutumab has a significant therapeutic effect in patients with relapsed or refractory multiple myeloma. In the once-weekly 0.4 mg/kg dose group, 74.1% of patients had at least a partial response to treatment, meaning their blood M protein levels were reduced by at least 50%. Among them, 51.5% of responding patients had a response lasting more than 9 months.

At the 0.8 mg/kg dose administered every two weeks, 71.7% of patients showed at least a partial response, and 76% of responders had responses that lasted at least nine months. M protein is an important blood marker commonly used to monitor treatment response in multiple myeloma. Studies have shown that Taquitumab can effectively reduce the level of M protein in patients' blood, indicating that it has significant efficacy in controlling the disease.

Reference materials:https://www.ema.europa.eu/en/medicines/human/EPAR/talvey